AR101130A1 - ANTICUERPOS DE UNIÓN A PROTOFIBRILLAS Ab MEJORADOS - Google Patents
ANTICUERPOS DE UNIÓN A PROTOFIBRILLAS Ab MEJORADOSInfo
- Publication number
- AR101130A1 AR101130A1 ARP150102178A ARP150102178A AR101130A1 AR 101130 A1 AR101130 A1 AR 101130A1 AR P150102178 A ARP150102178 A AR P150102178A AR P150102178 A ARP150102178 A AR P150102178A AR 101130 A1 AR101130 A1 AR 101130A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- binding fragment
- dementia
- disease
- subject
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 201000010374 Down Syndrome Diseases 0.000 abstract 4
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 4
- 201000002832 Lewy body dementia Diseases 0.000 abstract 4
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 4
- 230000009529 traumatic brain injury Effects 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 208000034799 Tauopathies Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Reivindicación 1: Un anticuerpo o fragmento de unión al antígeno del mismo que tiene afinidad frente a las protofibrillas Ab, caracterizado porque el anticuerpo o fragmento de unión al antígeno del mismo tiene una cadena liviana variable de acuerdo a la SEC ID Nº 8, en donde x¹ se selecciona de A, D, E y Q, o un análogo funcional del mismo; x² se selecciona de R, T, K, A y G, o un análogo funcional del mismo; x³ se selecciona de R, S, C, G y N, o un análogo funcional del mismo: y¹ se selecciona de V y A; y² se selecciona de I y V; y³ se selecciona de S y Q; y⁴ se selecciona de E y D; y opcionalmente una cadena pesada variable de acuerdo a la SEC ID Nº 14, en donde z¹ se selecciona de V y I; z² se selecciona de R y Q; y z³ se selecciona de A, N y T; con la excepción de la combinación x¹ = A, x² = R y x³ = R. Reivindicación 19: El uso de acuerdo a la reivindicación 18, caracterizado porque dichos otros trastornos asociados a la agregación de proteína Ab se seleccionan de lesión cerebral traumática (TBI), demencia por cuerpos de Lewy (LBD), síndrome de Down (DS), esclerosis lateral amiotrófica (ALS), demencia frontotemporal, tauopatías, amiloidosis sistémica, aterosclerosis y demencia por enfermedad de Parkinson (PDD). Reivindicación 20: Un método para reducir la cantidad de protofibrillas Ab en un sujeto, caracterizado porque comprende administrar a dicho sujeto una cantidad terapéuticamente efectiva del anticuerpo o fragmento de unión al antígeno de acuerdo a la reivindicaciones 1 a 14. Reivindicación 21: Un método para el tratamiento y/o profilaxis de enfermedad de Alzheimer en un sujeto que tiene, o que está en riesgo de desarrollar dicha enfermedad, caracterizado porque comprende administrar a dicho sujeto una cantidad terapéuticamente efectiva del anticuerpo o fragmento de unión al antígeno de acuerdo a la reivindicaciones 1 a 14. Reivindicación 25: Un método para el diagnóstico de lesión cerebral traumática (TBI), demencia por cuerpos de Lewy (LBD), síndrome de Down (DS), esclerosis lateral amiotrófica (ALS), demencia frontotemporal, tauopatías, amiloidosis sistémica, aterosclerosis y demencia por enfermedad de Parkinson (PDD) en personas que tienen o en riesgo de desarrollar cualquiera de dichas enfermedades, caracterizado porque comprende poner en contacto el tejido o fluido corporal de la persona, in vivo o in vitro, con el anticuerpo o fragmento de unión al antígeno de acuerdo a las reivindicaciones 1 a 14, o un fragmento del mismo, y medir la cantidad de dicho anticuerpo unido a la proteína Ab agregada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022952P | 2014-07-10 | 2014-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101130A1 true AR101130A1 (es) | 2016-11-23 |
Family
ID=53673920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102178A AR101130A1 (es) | 2014-07-10 | 2015-07-08 | ANTICUERPOS DE UNIÓN A PROTOFIBRILLAS Ab MEJORADOS |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9573994B2 (es) |
| EP (2) | EP3865510A3 (es) |
| JP (1) | JP6628786B2 (es) |
| KR (2) | KR102763164B1 (es) |
| CN (2) | CN112390881B (es) |
| AR (1) | AR101130A1 (es) |
| AU (1) | AU2015286707B2 (es) |
| CA (1) | CA2951990C (es) |
| CL (1) | CL2017000053A1 (es) |
| CO (1) | CO2017000346A2 (es) |
| CY (1) | CY1124563T1 (es) |
| DK (1) | DK3166970T3 (es) |
| ES (1) | ES2865112T3 (es) |
| HR (1) | HRP20210680T1 (es) |
| HU (1) | HUE053809T2 (es) |
| IL (2) | IL282823B2 (es) |
| JO (1) | JO3537B1 (es) |
| LT (1) | LT3166970T (es) |
| MA (2) | MA40224B1 (es) |
| MX (1) | MX379241B (es) |
| MY (1) | MY184890A (es) |
| PE (1) | PE20170768A1 (es) |
| PH (1) | PH12017500032B1 (es) |
| PL (1) | PL3166970T3 (es) |
| PT (1) | PT3166970T (es) |
| RS (1) | RS61717B1 (es) |
| RU (1) | RU2700104C2 (es) |
| SG (1) | SG11201610734RA (es) |
| SI (1) | SI3166970T1 (es) |
| SM (1) | SMT202100263T1 (es) |
| TW (1) | TWI678376B (es) |
| UA (1) | UA121550C2 (es) |
| WO (1) | WO2016005466A2 (es) |
| ZA (1) | ZA201706272B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017013599A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| WO2018011353A1 (en) | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
| SG10201913049QA (en) * | 2016-10-27 | 2020-02-27 | Eisai R&D Man Co Ltd | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EP3762031A4 (en) * | 2018-03-08 | 2021-12-22 | Phanes Therapeutics, Inc. | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREFORE |
| CN112805031A (zh) | 2018-07-24 | 2021-05-14 | 卫材R&D管理有限公司 | 阿尔茨海默病的治疗及预防方法 |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| US20250163135A1 (en) | 2021-07-09 | 2025-05-22 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| WO2023034230A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Mangement Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| EP4473009A1 (en) | 2022-02-02 | 2024-12-11 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| CN114578066B (zh) * | 2022-05-07 | 2022-08-19 | 北京第一生物化学药业有限公司 | 检测β-淀粉样蛋白的产品和方法 |
| US12084492B2 (en) | 2023-01-20 | 2024-09-10 | Mabwell Therapeutics, Inc. | Anti-amyloid beta protofibril/oligomer antibodies and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
| DE69126304T2 (de) | 1990-04-27 | 1997-09-04 | Mcmichael, John, Delanson, N.Y. | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
| US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| CA2174429C (en) | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
| CA2191101C (en) | 1994-05-25 | 2001-08-07 | Ellis L. Kline | Materials and methods for treatment of plaquing diseases |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性ａｐｐの定量法 |
| US6054114A (en) | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
| US20060178302A1 (en) | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
| US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| ES2253839T3 (es) | 1997-12-03 | 2006-06-01 | Neuralab, Ltd. | Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer. |
| WO2000039310A1 (en) | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Rubredoxin fusion proteins, protein expression system and methods |
| WO2000071671A2 (en) | 1999-05-26 | 2000-11-30 | New York University | New mutant genes in familial british dementia and familial danish dementia |
| PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| CA2378953A1 (en) | 1999-07-27 | 2001-02-01 | Abgenix, Inc. | Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| EP1571158B1 (en) | 1999-08-04 | 2009-10-14 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| BR0016022A (pt) | 1999-11-29 | 2002-08-06 | Neurochem Inc | Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide |
| AU7487301A (en) | 2000-05-22 | 2001-12-03 | Univ New York | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20030187011A1 (en) | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
| ES2368907T3 (es) | 2002-04-19 | 2011-11-23 | The Governing Council Of The University Of Toronto | Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer. |
| US20040049134A1 (en) | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
| US8871447B2 (en) | 2002-09-12 | 2014-10-28 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
| AU2003285151A1 (en) | 2002-11-04 | 2004-06-07 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| JP4668191B2 (ja) | 2003-08-20 | 2011-04-13 | アモールフィックス・ライフ・サイエンシィズ・リミテッド | タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法 |
| JP2007527865A (ja) | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
| SE0400707D0 (sv) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CA2572602A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta) |
| US20060079447A1 (en) | 2004-10-08 | 2006-04-13 | Wetzel Ronald B | Stabilized A-beta protofibrillar aggregates |
| US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| JP5173426B2 (ja) | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
| US20110020237A1 (en) | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| BRPI0608076A2 (pt) | 2005-03-05 | 2009-11-10 | Abbott Gmbh & Co Kg | método de seleção, processo para purificação de oligÈmeros beta-a não difusìveis, anticorpos seletivos contra os ditos oligÈmeros beta-a não difusìveis e um processo para fabricação dos ditos anticorpos |
| US7741448B2 (en) | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| CA2626783A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anti-addl monoclonal antibody and use thereof |
| EP1951892A4 (en) | 2005-11-22 | 2009-01-14 | Univ Pennsylvania | ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| UA100672C2 (en) * | 2006-07-14 | 2013-01-25 | Ас Иммуне Са | HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN |
| MY165105A (en) * | 2006-07-14 | 2018-02-28 | Ac Immune Sa | Humanized antibody against amyloid beta |
| WO2008060364A2 (en) * | 2006-10-02 | 2008-05-22 | Ac Immune S.A | Humani zed antibody against amyloid beta |
| WO2008156622A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
| CA2696164C (en) * | 2007-08-13 | 2018-06-12 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
| JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法 |
| HRP20171292T1 (hr) | 2007-11-16 | 2017-12-15 | The Rockfeller University | Polipeptidi i konjugati klorotoksina i njihove uporabe |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| BRPI1006448B1 (pt) | 2009-03-25 | 2021-08-17 | Genentech, Inc | Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3 |
| EP3892633A1 (en) | 2009-06-29 | 2021-10-13 | BioArctic AB | Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers |
| JP5692073B2 (ja) * | 2009-08-07 | 2015-04-01 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
| CN106397588B (zh) * | 2010-02-26 | 2020-09-08 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| JP5953303B2 (ja) * | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
| PT2654790T (pt) | 2010-12-22 | 2019-05-16 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpo modificado com semivida melhorada |
-
2015
- 2015-07-08 RU RU2017103446A patent/RU2700104C2/ru active
- 2015-07-08 PH PH1/2017/500032A patent/PH12017500032B1/en unknown
- 2015-07-08 LT LTEP15738876.0T patent/LT3166970T/lt unknown
- 2015-07-08 HR HRP20210680TT patent/HRP20210680T1/hr unknown
- 2015-07-08 TW TW104122215A patent/TWI678376B/zh active
- 2015-07-08 CA CA2951990A patent/CA2951990C/en active Active
- 2015-07-08 EP EP21154511.6A patent/EP3865510A3/en active Pending
- 2015-07-08 HU HUE15738876A patent/HUE053809T2/hu unknown
- 2015-07-08 PT PT157388760T patent/PT3166970T/pt unknown
- 2015-07-08 SM SM20210263T patent/SMT202100263T1/it unknown
- 2015-07-08 JP JP2017500897A patent/JP6628786B2/ja active Active
- 2015-07-08 MY MYPI2017700010A patent/MY184890A/en unknown
- 2015-07-08 US US14/794,172 patent/US9573994B2/en active Active
- 2015-07-08 EP EP15738876.0A patent/EP3166970B1/en active Active
- 2015-07-08 WO PCT/EP2015/065633 patent/WO2016005466A2/en not_active Ceased
- 2015-07-08 DK DK15738876.0T patent/DK3166970T3/da active
- 2015-07-08 RS RS20210459A patent/RS61717B1/sr unknown
- 2015-07-08 CN CN202011054114.6A patent/CN112390881B/zh active Active
- 2015-07-08 AU AU2015286707A patent/AU2015286707B2/en active Active
- 2015-07-08 PE PE2017000024A patent/PE20170768A1/es unknown
- 2015-07-08 KR KR1020237024350A patent/KR102763164B1/ko active Active
- 2015-07-08 MA MA40224A patent/MA40224B1/fr unknown
- 2015-07-08 MX MX2017000378A patent/MX379241B/es unknown
- 2015-07-08 AR ARP150102178A patent/AR101130A1/es active IP Right Grant
- 2015-07-08 CN CN201580036189.2A patent/CN106661103B/zh active Active
- 2015-07-08 IL IL282823A patent/IL282823B2/en unknown
- 2015-07-08 PL PL15738876T patent/PL3166970T3/pl unknown
- 2015-07-08 KR KR1020167037100A patent/KR102564384B1/ko active Active
- 2015-07-08 ES ES15738876T patent/ES2865112T3/es active Active
- 2015-07-08 JO JOP/2015/0167A patent/JO3537B1/ar active
- 2015-07-08 SG SG11201610734RA patent/SG11201610734RA/en unknown
- 2015-07-08 UA UAA201700962A patent/UA121550C2/uk unknown
- 2015-07-08 SI SI201531593T patent/SI3166970T1/sl unknown
- 2015-07-08 MA MA053887A patent/MA53887A/fr unknown
-
2017
- 2017-01-09 IL IL250001A patent/IL250001B/en active IP Right Grant
- 2017-01-09 CL CL2017000053A patent/CL2017000053A1/es unknown
- 2017-01-13 CO CONC2017/0000346A patent/CO2017000346A2/es unknown
- 2017-09-15 ZA ZA2017/06272A patent/ZA201706272B/en unknown
-
2021
- 2021-06-01 CY CY20211100477T patent/CY1124563T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101130A1 (es) | ANTICUERPOS DE UNIÓN A PROTOFIBRILLAS Ab MEJORADOS | |
| ZA201803396B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| CR20150016A (es) | Anticuerpo monoclonal | |
| MX2023001299A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| AR066987A1 (es) | Anticuerpo monoclonal contra proteina beta-amiloide | |
| EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| MX341369B (es) | Anticuerpo anti-beta-amiloide humanizado seguro y funcional. | |
| PH12013500615A1 (en) | Phosphospecific antibodies recognising tau | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| EP3405215A4 (en) | METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES | |
| CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| EP3801340A4 (en) | ELECTROTHERMAL THERAPY TO TREAT DISEASE OR UNWANTED TISSUE | |
| WO2008122441A3 (en) | Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases | |
| EA201890313A1 (ru) | Гуманизированные антитела к пироглутаматному варианту бета-амилоида | |
| EA201492162A1 (ru) | Антитела к трансглютаминазе 2 | |
| MX2020009532A (es) | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| EP3802568A4 (en) | PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |